Sign Up for Free Access to the
Latest Clinical Updates in Your Specialty!

Receive conference highlights, journal articles, and online medical education activities straight to your inbox.

Never Miss an Update

Foreword – touchREVIEWS in Oncology & Haematology, Volume 21, Issue 1, 2025

We are delighted to present the latest edition of touchREVIEWS in Oncology & Haematology. This issue underscores the evolving landscape of cancer therapeutics, showcasing advances across a wide range of malignancies, from haematologic diseases to solid tumours, through novel mechanisms, emerging biomarkers and personalized treatment strategies. We begin with an editorial by Isabela Wen-Chi Chang […]

Genitourinary Cancer

6 mins

Morgan Rouprêt, ESOU22: Highlights from the Conference

Published Online: Feb 18th 2022

touchONCOLOGY are joined by the EAU Section of Oncological Urology (ESOU) Chairman Professor Morgan Rouprêt to discuss his highlights from the 2022 conference.

Questions

Could you tell us a little about the this year’s EAU Section of Oncological Urology (ESOU22) and how well it went? (00:34-01:42)
What were this year’s hot topics in genito-urinary cancer at ESOU22? (01:42-06:25)

Speaker Disclosure: Morgan Rouprêt has no conflicts of interest to declare in relation to this video.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.

Filmed in coverage of the EAU Section of Oncological Urology (ESOU) 2022 conference.

Durvalumab with neoadjuvant chemotherapy and radical cystectomy in muscle-invasive bladder cancer

Thomas Powles

The NIAGARA trial evaluated the combination of durvalumab (D) with neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) and adjuvant durvalumab in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC). A total of 1063 patients were randomized to either receive durvalumab + NAC + RC followed by adjuvant durvalumab or NAC + RC alone. The study […]

Related Videos in Genitourinary Cancer

Developed by Touch

Insights in bladder cancer: EV-302, EV-101, CheckMate 901

Petros Grivas

Significant advancements in bladder cancer research emerged from ASCO 2024. To understand these, as well as the other key trials and highlights from the meeting, we spoke with the Clinical Director of the Genitourinary Cancer Program at the University of Washington and Fred Hutchinson Cancer Center, Prof. Petros Grivas. In this interview, Prof. Grivas delves into the findings from the EV-302 (NCT04223856), EV-101 (NCT02091999), EV-201 (NCT03219333), EV-301 (NCT03474107), CheckMate 901 (NCT03036098) and other trials, offering his valuable insights into the impact the results could have on clinical practice, and particularly in the treatment of bladder

Developed by Touch

Highlights in genitourinary cancers (non-prostate) - SunRISe-1, THOR-2, EV-302 CheckMate 901: Petros Grivas, ESMO 2023

ESMO 2023 brought forth some practice-changing data in the field of non-prostate genitourinary cancer. To understand these, as well as the other key trials and highlights from the meeting, we engaged in a conversation with the Clinical Director of the Genitourinary ...

Developed by Touch

Top 5 tips for a successful career in medical oncology: Petros Grivas, ESMO 2023

As part the Young Oncologists session, at ESMO 2023, Prof. Petros Grivas (Clinical Director of the Genitourinary Cancer Program, University of Washington and Fred Hutchinson Cancer Center, Seattle, USA) and colleagues, spent time speaking with medial students and early-career physicians about ...

Developed by Touch

ARPi vs. SOC and taxanes in mCRPC - ProBio study: Henrik Grönberg, EMSO 2023

The uniquely designed Prostate Biomarker (ProBio) study (NCT03903835) used outcome-adaptive randomization to compare biomarker-driven treatment selection against physician’s choice, and to compare androgen receptor inhibitors (ARPIs) against standard-of-care (SOC) and taxanes in castrate-resistant prostate cancer (mCRPC). To learn more ...

Developed by Touch

Looking to the future with Arnulf Stenzl: What can we hope to see in urological oncology in the next 5 years?

Secretary General of the European Association of Urology (EAU), Prof Arnulf Stenzl, discusses what he hopes to see in the field of uro-oncological surgery in the next five years. He hopes this will include improving early detection of prostate cancer ...

Developed by Touch

Arnulf Stenzl, EAU23: Latest developments in urological oncology

It was a pleasure to hear from the Secretary General of the European Association of Urology (EAU), Prof Arnulf Stenzl, to discuss some of the pivotal new projects and initiatives the society are currently working on. Topics covered Minimalise any ...

Developed by Touch

Arnulf Stenzl: Pivotal new projects of the European Association of Urology (EAU)

Developed by Touch

Arnulf Stenzl: Highlights from EAU23!

touchONCOLOGY caught up with the Secretary General of the European Association of Urology (EAU), Prof Arnulf Stenzl, to discuss some of the key advances from the conference. He focusses this interview on prostate cancer, early detection, systemic therapy, new therapies ...

Axel Merseburger: Current advances in prostate cancer treatment options and what we might expect in the next 5 years

Our Editor-in-Chief Axel Merseburger (Lübeck University, Lübeck, Germany) discusses the most important recent advances in the treatment landscape for prostate cancer, including screening using MRI and PSMA PET-CT scans, and triplet therapies using hormone therapy and PARP inhibitors. ...

Developed by Touch

Axel Merseburger: Highlights of EAU23

Our Editor-in-Chief Axel Merseburger (Lübeck University, Lübeck, Germany) discusses key data from this year's European Association of Urology annual meeting (EAU23) in the field of prostate cancer. He discusses results from the LuTectomy trial, the 15-year update of ...

Developed by Touch

Sebastian Schmid, ESMO 2022: RACE-IT - RAdiation therapy before radical CystEctomy combined with ImmunoTherapy in advanced bladder cancer

Patients with locally advanced bladder cancer have a poor prognosis despite surgical therapy. Prof. Sebastian Schmid (Technical University of Munich, Munich, Germany) joins touchONCOLOGY to discuss the unmet needs in the treatment of locally advanced bladder cancer, and also discusses ...

Developed by Touch

Jonathan Rosenberg, ESMO 2022: Study EV-103 Cohort K - Enfortumab vedotin in combination with pembrolizumab in locally advanced or metastatic urothelial cancer

As there is a current need for effective and tolerable first line treatment options in patients with locally advanced or metastatic urothelial cancer (la/mUC), Dr Jonathan Rosenberg (Memorial Sloan Kettering Cancer Center, New York, NY, USA) joins touchONCOLOGY to ...

Latest articles videos and clinical updates - straight to your inbox

Log into your Touch Account

Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.

Error:

Forgot Password?

Or log in with

By proceeding, you agree to our terms & conditions.

For information about how we
use your data, see our privacy policy.

Register now for FREE Access

Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.

Already have an Account?

Sign up with an Email

Or use a Social Account.

Error:

By clicking sign up you agree to the website
terms & conditions and privacy policy.

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Sign Up for Free Access to the
Latest Clinical Updates in Your Specialty!

Learning Activities

Journals

Specialities

Foreword – touchREVIEWS in Oncology & Haematology, Volume 21, Issue 1, 2025

Learning Activities

Journals

Specialities

Foreword – touchREVIEWS in Oncology & Haematology, Volume 21, Issue 1, 2025

Morgan Rouprêt, ESOU22: Highlights from the Conference

Durvalumab with neoadjuvant chemotherapy and radical cystectomy in muscle-invasive bladder cancer

Insights in bladder cancer: EV-302, EV-101, CheckMate 901

Highlights in genitourinary cancers (non-prostate) - SunRISe-1, THOR-2, EV-302 CheckMate 901: Petros Grivas, ESMO 2023

Top 5 tips for a successful career in medical oncology: Petros Grivas, ESMO 2023

ARPi vs. SOC and taxanes in mCRPC - ProBio study: Henrik Grönberg, EMSO 2023

Looking to the future with Arnulf Stenzl: What can we hope to see in urological oncology in the next 5 years?

Arnulf Stenzl, EAU23: Latest developments in urological oncology

Arnulf Stenzl: Pivotal new projects of the European Association of Urology (EAU)

Arnulf Stenzl: Highlights from EAU23!

Axel Merseburger: Current advances in prostate cancer treatment options and what we might expect in the next 5 years

Axel Merseburger: Highlights of EAU23

Sebastian Schmid, ESMO 2022: RACE-IT - RAdiation therapy before radical CystEctomy combined with ImmunoTherapy in advanced bladder cancer

Jonathan Rosenberg, ESMO 2022: Study EV-103 Cohort K - Enfortumab vedotin in combination with pembrolizumab in locally advanced or metastatic urothelial cancer

Latest articles videos and clinical updates - straight to your inbox

Connect With Us

Useful Links

In Partnership With

Specialities

Sign Up for Free Access to the Latest Clinical Updates in Your Specialty!

Learning Activities

Journals

Specialities

Trending Topic

Connect With Us:

Morgan Rouprêt, ESOU22: Highlights from the Conference

Latest articles videos and clinical updates - straight to your inbox

Log into your Touch Account

Register now for FREE Access

Sign up with an Email

This Functionality is forMembers Only

Sign Up for Free Access to the
Latest Clinical Updates in Your Specialty!

This Functionality is for
Members Only